Stay updated on Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision bumped from v3.6.4 to v3.6.5, reflecting a minor page version update. It does not modify study content or user-facing information.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page's version tag was updated from v3.6.3 to v3.6.4, signaling a minor platform update with no changes to the study details.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a small update to the page version.SummaryDifference0.1%

- Check56 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing the previous v3.6.0, indicating an updated page version.SummaryDifference0.1%

- Check71 days agoChange DetectedRecruitment status now indicates no participants are being sought, and new guidance sections were added to help users read the study record and join the study. The revision tag was updated to v3.6.0 and the Intervention/Treatment heading formatting was adjusted.SummaryDifference0.6%

- Check78 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5, indicating a minor update to the page version.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.